Lilly swoops on Dermira to claim Dupixent rival

Regeneron/Sanofi get EU okay for Dupixent in “asthma of the ...

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

Sanofi’s Dupixent backed for nasal polyps use in Europe

Sanofi's eczema drug gets EU approval to treat adolescents

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.